Disclaimer: This blog is for informational and educational purposes only, intended for healthcare professionals and organizations. It does not constitute medical or professional advice. Full disclaimer here.
For decades, Canada has required that drugs be both safe and effective before being approved for market use, aligning with international best practices. However, recent U.S. policy discussions—including proposals like the Promising Pathway Act—aim to lower or even eliminate the requirement for drugs to demonstrate effectiveness before being marketed. While these proposals are framed as increasing access to new treatments, they pose significant risks to public health and could influence similar regulatory discussions in Canada.
🇨🇦 What’s the Canadian Context?
- Canada’s own thalidomide tragedy (1960s) played a key role in shaping modern drug regulation. The drug, marketed for morning sickness, caused severe birth defects, reinforcing the need for rigorous pre-approval testing.
- Health Canada follows an evidence-based approach similar to the FDA’s, requiring both safety and efficacy data for drug approvals. However, industry pressure and the push for “fast-tracked” approvals continue to challenge this framework.
- Recent concerns with Alzheimer’s drugs like Aducanumabshow how even in a rigorous system, pressures to approve treatments based on limited evidence persist. Canada never approved the drug.
Why This Matters to Canadians
🔹 Safety and effectiveness must go hand in hand – If a drug does not work, any associated risk is unjustifiable. Lowering approval standards could lead to the widespread use of ineffective treatments, harming patients and straining healthcare resources.
🔹 Postmarket studies alone are challenging – Experience in both Canada and the U.S. has shown that once a drug is approved, companies often fail to complete follow-up studies to confirm long-term benefits. This has been seen with some cancer therapies and rare disease treatments, where postmarket data collection has been slow or nonexistent.
🔹 Patients deserve real choices, not false hope – While patients with serious conditions may be willing to try unproven treatments, they need clear, evidence-based information to make informed decisions. Regulatory agencies must ensure that approval standards protect patient autonomy rather than being eroded by industry pressures.
What’s Next?
Health Canada has been exploring “adaptive” approval models, similar to the U.S. FDA’s accelerated pathways. While flexibility in drug approval can be valuable, we must avoid repeating past mistakes by ensuring that effectiveness standards remain strong.
For a deeper dive into this issue, the recent JAMA article by Zettler et al. (2025) provides a critical analysis of these policy changes: DOI: 10.1001/jama.2025.2807.
(https://jamanetwork.com/journals/jama/fullarticle/2831275)
👉 Should Canada follow the U.S. in lowering drug approval standards, or should we reinforce our commitment to evidence-based regulation? Let’s discuss.
#HealthCanada #DrugApproval #PatientSafety #HealthcarePolicy #MedicalEthics #EvidenceBasedMedicine
